AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 273 USD | -0.19% |
|
+3.39% | -5.21% |
| Apr. 22 | Wall Street: tech and SOXX in free fall this week | CF |
| Apr. 19 | Wall Street: tech and SOXX in free fall this week | CF |
Financials (USD)
| Sales 2024 * | 32.95B | Sales 2025 * | 34.14B | Capitalization | 147B |
|---|---|---|---|---|---|
| Net income 2024 * | 6.12B | Net income 2025 * | 7.56B | EV / Sales 2024 * | 5.86 x |
| Net Debt 2024 * | 46.47B | Net Debt 2025 * | 40.28B | EV / Sales 2025 * | 5.48 x |
| P/E ratio 2024 * |
23.8
x | P/E ratio 2025 * |
18.4
x | Employees | 26,700 |
| Yield 2024 * |
3.39% | Yield 2025 * |
3.67% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | +0.17% | ||
| 1 week | +3.85% | ||
| Current month | -3.55% | ||
| 1 month | -2.34% | ||
| 3 months | -10.23% | ||
| 6 months | -0.68% | ||
| Current year | -4.78% |
1 week
260.68
274.86
1 month
260.68288.57
Current year
260.68329.72
1 year
211.71329.72
3 years
198.64329.72
5 years
166.30329.72
10 years
108.20329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 06-05-31 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 19-10-22 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | Dec. 17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 17-02-02 |
Ellen Kullman
BRD | Director/Board Member | 68 | 16-10-13 |
Robert Williams
BRD | Director/Board Member | 75 | 14-10-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 120 M€ | +11.28% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 273 | -0.19% | 2 458 672 |
| 24-04-23 | 273.5 | +0.60% | 2,493,321 |
| 24-04-22 | 271.9 | +1.11% | 2,165,755 |
| 24-04-19 | 268.9 | +2.35% | 3,380,330 |
| 24-04-18 | 262.8 | -0.50% | 2,082,791 |
Delayed Quote Nasdaq, April 24, 2024 at 02:17 pm EDT
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
273.5
USD
Average target price
300.3
USD
Spread / Average Target
+9.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.78% | 147B | |
| +26.06% | 672B | |
| +25.87% | 570B | |
| -5.34% | 360B | |
| +16.66% | 321B | |
| +8.42% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.81% | 149B |
- Stock Market
- Equities
- AMGN Stock
